Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …

The progression of cancer involves not only the gradual evolution of cells by mutations in
DNA but also alterations in the gene expression induced by those mutations and input from …

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with a limited set of
known driver mutations but considerable cancer cell heterogeneity. Phosphoproteomics …

Nanoparticles have been explored in glioblastomas as they can traverse the blood–brain
barrier and target glioblastoma selectively. However, direct observation of nanoparticle …

A major pharmacological assumption is that lowering disease-promoting protein levels is
generally beneficial. For example, inhibiting metastasis activator BACH1 is proposed to …

Targeted strategies against specific driver molecules of cancer have brought about many
advances in cancer treatment since the early success of the first small-molecule inhibitor …

Raf Kinase Inhibitory Protein (RKIP) maintains cellular robustness and prevents the
progression of diseases such as cancer and heart disease by regulating key kinase …

Epithelial–mesenchymal transition (EMT) is an important axis of phenotypic plasticity—a
hallmark of cancer metastasis. Raf kinase-B inhibitor protein (RKIP) and BTB and CNC …

Thousand-and-one–amino acid kinase 3 (TAOK3) is a serine and threonine kinase that
belongs to the STE-20 family of kinases. Its absence reduces T cell receptor (TCR) signaling …

RNA interference is a promising way to treat cancer and the construction of a stable drug
delivery system is critically important for its application. Gelatin nanospheres (GNs) comprise …